ArticleCurrent therapeutic research, clinical and experimental2015
Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors.
Article in Current therapeutic research, clinical and experimental, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 40 citations in OpenAlex.
- Disarming Pseudomonas aeruginosa: repurposing vardenafil, valsartan, and olmesartan as anti-virulence and antibiofilm agents.Scientific reports · 2026Article
- Article
- Development of Ciprofloxacin-Loaded Bilosomes In-Situ Gel for Ocular Delivery: Optimization, In-Vitro Characterization, Ex-Vivo Permeation, and Antimicrobial Study.Gels (Basel, Switzerland) · 2022Article
- Study the Ability ofArchives of Razi Institute · 2022Article
- Development and evaluation of ciprofloxacin-bacterial cellulose composites produced through in situ incorporation method.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- Fabrication of New Multifunctional Cotton/Lycra Composites Protective Textiles through Deposition of Nano Silica Coating.Polymers · 2021Article
- Modulatory Effects of Caffeine and Pentoxifylline on Aromatic Antibiotics: A Role for Hetero-Complex Formation.Molecules (Basel, Switzerland) · 2021Article
- Multifunctional lipid-based nanocarriers with antibacterial and anti-inflammatory activities for treating MRSA bacteremia in mice.Journal of nanobiotechnology · 2021Article
- A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- The Role of Phosphodiesterase Inhibitors in the Management of Cavernositis With Multifocal Abscesses: A Report of Case Series.Sexual medicine · 2020Article
- Vitamin D Pretreatment Attenuates Ciprofloxacin-Induced Antibacterial Activity.Clinical pharmacology : advances and applications · 2020Article
- Possible involvement of ROS generation in vorinostat pretreatment induced enhancement of the antibacterial activity of ciprofloxacin.Clinical pharmacology : advances and applications · 2017Article
- Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.Drug design, development and therapy · 2016Article
- Construction of antimicrobial peptide-drug combination networks from scientific literature based on a semi-automated curation workflow.Database : the journal of biological databases and curation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCiprofloxacin is a commonly used antibiotic for urinary tract infection that interacts with bacterial topoisomerases leading to oxidative radicals generation and bacterial cell death. Phosphodiesterase inhibitors (PDEis), on the other hand, are commonly used drugs for the management of erectile dysfunction. The group includes agents such as sildenafil, vardenafil, and tadalafil.
objectivesWe investigated whether PDEi could interfere with the antibacterial activity of ciprofloxacin.
methodsPDEis were tested in several reference bacteria, including Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis, Acinetobacter baumannii, Proteus mirabilis, and Klebsiella pneumoniae utilizing a standard disc diffusion method and measuring both zones of inhibition and MIC.
resultsResults from both assays indicated that ciprofloxacin demonstrates potent activity against the tested reference bacteria. Additionally, when bacteria were treated with a combination of ciprofloxacin and sildenafil, tadalafil, or vardenafil, the zones of the combination inhibition were significantly reduced, whereas the MIC values were significantly greater than those of ciprofloxacin alone for all tested bacterial strains. In an attempt to examine the mechanism by which PDEis interfere with the action of ciprofloxacin, we utilized the in vitro E coli DNA gyrase cleavage assay. The results showed that PDEi drugs had no effect on ciprofloxacin's inhibition of E coli gyrase activity.
conclusionsPretreatment of various reference bacterial cells with PDEis largely inhibited the antibacterial activity of ciprofloxacin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.